Perspective · 19 Mar 2025
Research articlePublished 10 Jan 2023
The Effect of Adjuvants and Immune Routes on the Immunodominance of Epitopes and Protection Efficacy of SARS-CoV-2 RBD Antigen
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Previous studies have revealed that the Receptor-Binding Domain (RBD) of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein is immunogenic in both mice and healthy volunteers, and humoral immune response plays a key role in RBD-mediated protection. In this study, we investigated the immunogenicity and protective efficacy of immunization with RBD plus three different adjuvants (Al(OH)3, ASO3, and AddaVax) against SARS-CoV-2 pseudo virus through two different routes (intramuscular or intranasal immunization) in mice. The results showed that the immunogenicity and titer of neutralizing antibodies changed in response to different adjuvants and immune routes. Furthermore, six B-cell immunodominant epitopes (RBD1-18, RBD49-66, RBD61-78, RBD97-114, RBD139-156, and RBD145-162) in RBD were identified using antisera from a different immunized group, which may explain the differences in protection observed in each immunized group. Through sequence alignment, we found that six B-cell epitopes are highly conserved among different SARS-COV-2 variants (including Alpha-, Beta-, Gamma- and Omicron-Variant). This study indicated that the immunodominance of epitopes and protection efficacy of RBD antigen are different by different adjuvants and immune routes, which may further guide adjuvant screening for vaccine development and optimization.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Immunotherapy: Open Access.
Perspective · 19 Mar 2025
Advancing Immunotherapy: Future Directions in the Fight against Renal Cell Carcinoma
Short communication · 19 Mar 2025
Emerging Therapies: The Latest Developments in Autoimmune Disease Management
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalImmunotherapy: Open Access
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Sisi Li”
- BylineArticles whose byline prints “Lianli Duan”
- BylineArticles whose byline prints “Xiaoli Zhang”
- BylineArticles whose byline prints “Rui Yang”
- BylineArticles whose byline prints “Longlong Chen”
- BylineArticles whose byline prints “Zhifu Chen”
- BylineArticles whose byline prints “Qiang Gou”
- BylineArticles whose byline prints “Wenxin Bao”
